Pharmacokinetic/Pharmacodynamic Evaluation of Ivosidenib or Enasidenib Combined With Intensive Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed IDH1/2‐Mutant Acute Myeloid Leukemia

Mutant isocitrate dehydrogenase 1/2 (mIDH1/2) proteins catalyze production of the oncometabolite D‐2‐hydroxyglutarate (2‐HG). Ivosidenib and enasidenib are oral inhibitors of mIDH1 and mIDH2, respectively. An open‐label phase 1 study is evaluating the safety and efficacy of ivosidenib or enasidenib...

Descripción completa

Detalles Bibliográficos
Autores principales: Fan, Bin, Chen, Yue, Yin, Feng, Hua, Lei, Almon, Caroline, Nabhan, Salah, Cooper, Michael, Yang, Hua, Hossain, Mohammad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9303875/
https://www.ncbi.nlm.nih.gov/pubmed/35166065
http://dx.doi.org/10.1002/cpdd.1067

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9303875/
https://www.ncbi.nlm.nih.gov/pubmed/35166065
http://dx.doi.org/10.1002/cpdd.1067

Ejemplares similares